Patasius A, Smailyte G, Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38–52.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.
Article CAS PubMed Google Scholar
Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018;7:F1000.
Article PubMed Central PubMed Google Scholar
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.
Article CAS PubMed Google Scholar
Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol. 2018;200:956–66.
Article CAS PubMed Google Scholar
Niu Y, Guo C, Wen S, Tian J, Luo J, Wang K, Tian H, Yeh S, Chang C. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Lett. 2018;439:47–55.
Article CAS PubMed Google Scholar
Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999;155:641–7.
Article CAS PubMed Central PubMed Google Scholar
Bonkhoff H. Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. Prostate. 2018;78:2–10.
Article CAS PubMed Google Scholar
Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70:214–8.
Article CAS PubMed Central PubMed Google Scholar
Shen Y, Cao J, Liang Z, Lin Q, Wang J, Yang X, Zhang R, Zong J, Du X, Peng Y, et al. Estrogen receptor alpha-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer. Cell Commun Signal. 2019;17:50.
Article PubMed Central PubMed Google Scholar
Liang Z, Cao J, Tian L, Shen Y, Yang X, Lin Q, Zhang R, Liu H, Du X, Shi J, Zhang J. Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-alpha/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer. Cancer Lett. 2019;467:72–84.
Article CAS PubMed Google Scholar
Mondal D, Narwani D, Notta S, Ghaffar D, Mardhekar N, Quadri SSA. Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators. Cancer Drug Resist. 2021;4:96–124.
CAS PubMed Central PubMed Google Scholar
Khurana N, Sikka SC. Targeting Crosstalk between Nrf-2, NF-kappaB and androgen receptor signaling in prostate cancer. Cancers (Basel). 2018;10:352.
Endo S, Kawai M, Hoshi M, Segawa J, Fujita M, Matsukawa T, Fujimoto N, Matsunaga T, Ikari A. Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells. J Biochem. 2021;170:89–96.
Article CAS PubMed Google Scholar
Bellezza I, Scarpelli P, Pizzo SV, Grottelli S, Costanzi E, Minelli A. ROS-independent Nrf2 activation in prostate cancer. Oncotarget. 2017;8:67506–18.
Article PubMed Central PubMed Google Scholar
Wu J, Williams D, Walter GA, Thompson WE, Sidell N. Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells. Exp Cell Res. 2014;328:351–60.
Article CAS PubMed Google Scholar
Meng X, Wang M, Wang X, Sun G, Ye J, Xu H, Sun X. Suppression of NADPH oxidase- and mitochondrion-derived superoxide by Notoginsenoside R1 protects against cerebral ischemia-reperfusion injury through estrogen receptor-dependent activation of Akt/Nrf2 pathways. Free Radic Res. 2014;48:823–38.
Article CAS PubMed Google Scholar
Zhang B, Zhang J, Zhang C, Zhang X, Ye J, Kuang S, Sun G, Sun X. Notoginsenoside R1 protects against diabetic cardiomyopathy through activating estrogen receptor alpha and its downstream signaling. Front Pharmacol. 2018;9:1227.
Article CAS PubMed Central PubMed Google Scholar
Oh JY, Choi GE, Lee HJ, Jung YH, Chae CW, Kim JS, Lee CK, Han HJ. 17beta-Estradiol protects mesenchymal stem cells against high glucose-induced mitochondrial oxidants production via Nrf2/Sirt3/MnSOD signaling. Free Radic Biol Med. 2019;130:328–42.
Article CAS PubMed Google Scholar
Chu C, Gao X, Li X, Zhang X, Ma R, Jia Y, Li D, Wang D, Xu F. Involvement of estrogen receptor-alpha in the activation of Nrf2-antioxidative signaling pathways by silibinin in pancreatic beta-cells. Biomol Ther (Seoul). 2020;28:163–71.
Ansell PJ, Lo SC, Newton LG, Espinosa-Nicholas C, Zhang DD, Liu JH, Hannink M, Lubahn DB. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. Mol Cell Endocrinol. 2005;243:27–34.
Article CAS PubMed Google Scholar
Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005;11:6823–34.
Article CAS PubMed Central PubMed Google Scholar
Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate. 2009;69:1119–27.
Article CAS PubMed Central PubMed Google Scholar
Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007;7:64.
Article PubMed Central PubMed Google Scholar
Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790–9.
Article CAS PubMed Google Scholar
Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chery L, True LD, Higano CS, Montgomery B, et al. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate. 2016;76:810–22.
Article CAS PubMed Central PubMed Google Scholar
Chen HH, Chiu YC, Zhang T, Zhang S, Huang Y, Chen Y. GSAE: an autoencoder with embedded gene-set nodes for genomics functional characterization. BMC Syst Biol. 2018;12:142.
Article CAS PubMed Central PubMed Google Scholar
Peng Y, Shi J, Du X, Wang L, Klocker H, Mo L, Mo Z, Zhang J. Prostaglandin E2 induces stromal cell-derived factor-1 expression in prostate stromal cells by activating protein kinase A and transcription factor Sp1. Int J Biochem Cell Biol. 2013;45:521–30.
Article CAS PubMed Google Scholar
Zhang Z, Duan L, Du X, Ma H, Park I, Lee C, Zhang J, Shi J. The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate. 2008;68:508–16.
Article CAS PubMed Google Scholar
Wu Q, Shi J, Chen L, Wang CY, Park I, Lee C, Zhang J. Regulation of proliferation and differentiation of prostatic stromal cells by oestradiol through prostatic epithelial cells in a paracrine manner. BJU Int. 2008;101:497–502.
Article CAS PubMed Google Scholar
Jia B, Gao Y, Li M, Shi J, Peng Y, Du X, Klocker H, Sampson N, Shen Y, Liu M, Zhang J. GPR30 promotes prostate stromal cell activation via suppression of ERalpha expression and its downstream signaling pathway. Endocrinology. 2016;157:3023–35.
Article CAS PubMed Google Scholar
Wang CY, Shi JD, Yan CH, Wu Q, Klocker H, Park I, Lee C, Zhang J. Development of a cell-isolation method for human prostatic smooth muscle cells based on cell type-specific activation of the SM22 gene promoter. BJU Int. 2007;99:183–8.
Article CAS PubMed Google Scholar
Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A. 2005;102:6201–6.
Article CAS PubMed Central PubMed Google Scholar
Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198–210.
留言 (0)